Carvedilol controlled-release - Chong Kun Dang

Drug Profile

Carvedilol controlled-release - Chong Kun Dang

Alternative Names: Carvedilol sustained-release - Chong Kun Dang; CKD-825; Dilatrend SR

Latest Information Update: 05 May 2016

Price : $50

At a glance

  • Originator Chong Kun Dang
  • Class Antihypertensives; Carbazoles; Ethanolamines; Heart failure therapies; Ischaemic heart disorder therapies; Phenyl ethers; Propanolamines; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor antagonists; Alpha beta adrenergic receptor antagonists; Beta-adrenergic receptor antagonists; Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Angina pectoris; Essential hypertension; Heart failure

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 30 Sep 2013 Chong Kun Dang completes a phase III trial in Essential hypertension in South Korea (NCT01756430)
  • 01 Feb 2013 Launched before February 2013 for Angina pectoris in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top